SANOFI ADR

NASDAQ: SNY (Sanofi)

Last update: 10 Oct, 11:45PM

48.09

-0.73 (-1.50%)

Previous Close 48.82
Open 48.98
Volume 2,580,216
Avg. Volume (3M) 3,042,337
Market Cap 120,193,523,712
Price / Earnings (TTM) 16.03
Price / Earnings (Forward) 9.97
Price / Sales 2.33
Price / Book 1.49
52 Weeks Range
44.62 (-7%) — 60.12 (25%)
Earnings Date 24 Oct 2025
TTM Dividend Yield 4.60%
Profit Margin 13.95%
Operating Margin (TTM) 20.78%
Diluted EPS (TTM) 2.94
Quarterly Revenue Growth (YOY) -4.60%
Quarterly Earnings Growth (YOY) 65.20%
Total Debt/Equity (MRQ) 23.01%
Current Ratio (MRQ) 1.46
Operating Cash Flow (TTM) 9.08 B
Levered Free Cash Flow (TTM) -4.94 B
Return on Assets (TTM) 4.28%
Return on Equity (TTM) 7.30%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bearish
Drug Manufacturers - General (Global) Bullish Bearish
Stock Sanofi Bearish Bearish

AIStockmoo Score

1.3
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -1.0
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 1.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SNY 120 B 4.60% 16.03 1.49
AZN 263 B 1.85% 31.96 5.80
AMGN 161 B 3.14% 24.45 21.55
GILD 141 B 2.08% 23.78 6.97
GRFS 6 B 1.73% 28.00 1.12
BIIB 21 B - 13.64 1.29

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Institutions 10.49%

Ownership

Name Date Shares Held
Beryl Capital Management Llc 30 Jun 2025 4,606,267
52 Weeks Range
44.62 (-7%) — 60.12 (25%)
Median 58.00 (20.61%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
Morgan Stanley 08 Sep 2025 58.00 (20.61%) Buy 46.80

No data within this time range.

Date Type Details
20 Oct 2025 Announcement Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
20 Oct 2025 Announcement Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
20 Oct 2025 Announcement Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 Announcement Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 Announcement Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 Announcement Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
20 Oct 2025 Announcement Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
17 Oct 2025 Announcement Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
17 Oct 2025 Announcement Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
17 Oct 2025 Announcement Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
17 Oct 2025 Announcement Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
16 Oct 2025 Announcement EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
14 Oct 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - September 2025
08 Oct 2025 Announcement Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08 Oct 2025 Announcement Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08 Oct 2025 Announcement Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
02 Oct 2025 Announcement Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
26 Sep 2025 Announcement Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
24 Sep 2025 Announcement Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24 Sep 2025 Announcement Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24 Sep 2025 Announcement Press release: Availability of the Q3 2025 Aide mémoire
24 Sep 2025 Announcement Press release: Availability of the Q3 2025 Aide mémoire
23 Sep 2025 Announcement Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
23 Sep 2025 Announcement Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
22 Sep 2025 Announcement Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22 Sep 2025 Announcement Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22 Sep 2025 Announcement Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
22 Sep 2025 Announcement Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
17 Sep 2025 Announcement Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
17 Sep 2025 Announcement Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
12 Sep 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - August 2025
11 Sep 2025 Announcement Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
11 Sep 2025 Announcement Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
10 Sep 2025 Announcement Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
10 Sep 2025 Announcement Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
10 Sep 2025 Announcement Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
04 Sep 2025 Announcement Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
04 Sep 2025 Announcement Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
04 Sep 2025 Announcement Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
29 Aug 2025 Announcement Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
29 Aug 2025 Announcement Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
26 Aug 2025 Announcement New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week
18 Aug 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - July 2025
14 Aug 2025 Announcement Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
14 Aug 2025 Announcement Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
06 Aug 2025 Announcement Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
06 Aug 2025 Announcement Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
31 Jul 2025 Announcement Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
31 Jul 2025 Announcement Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
31 Jul 2025 Announcement Press release: Online availability of Sanofi’s half-year financial report for 2025
31 Jul 2025 Announcement Press release: Online availability of Sanofi’s half-year financial report for 2025
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
30 Jul 2025 Announcement Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
30 Jul 2025 Announcement Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
25 Jul 2025 Announcement Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
25 Jul 2025 Announcement Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Show more
TTM Dividend Yield 4.60%
5Y Average Dividend Yield 4.78%
Payout Ratio 75.37%
Expected Next Dividend Payment Jun 2026
Ex Date Announcement Date Payment Date Details
09 May 2025 15 Apr 2025 12 Jun 2025 2.212154 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Cash
30 May 2023 - 23 Jun 2023 1.9000852 Cash
26 May 2022 - 27 Jun 2022 0.2971788 Cash
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Cash
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Cash
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Cash
07 May 2019 - 31 May 2019 1.722322 Cash
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Cash
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Cash
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Cash
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Cash
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Cash
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Cash
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Cash
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 2.21 1 4.60
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria